ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02282605
Recruitment Status : Completed
First Posted : November 4, 2014
Results First Posted : October 7, 2016
Last Update Posted : October 7, 2016
Sponsor:
Information provided by (Responsible Party):
Destiny Pharma Plc

Brief Summary:
Study to determine the efficacy, safety and tolerability of two concentrations of XF-73 nasal gel in combination with body and face washing with chlorhexidine gluconate cloths in eradicating nasal carriage of Staphylococcus aureus.

Condition or disease Intervention/treatment Phase
Staphylococcus Aureus Infection Drug: XF-73 nasal gel Drug: Placebo nasal gel Other: Chlorhexidine gluconate 2% topical cloths Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase I/II Randomised, Double-blind, Placebo-controlled, Single Centre Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of Two Concentrations of XF-73 Nasal Gel in Healthy Subjects.
Study Start Date : September 2014
Actual Primary Completion Date : November 2014
Actual Study Completion Date : November 2014

Arm Intervention/treatment
Experimental: XF-73 2.0 mg/g nasal gel
0.3mL (nominal 300 microgram) XF-73 nasal gel will be applied to each naris, twice daily for two days. Each dose will be 0.3mL per naris/0.6mL per dose delivering 0.6mg XF-73 per naris/1.2mg XF-73 per dose. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
Drug: XF-73 nasal gel
Other: Chlorhexidine gluconate 2% topical cloths
Experimental: XF-73 0.5 mg/g nasal gel
0.3mL (nominal 300 microgram) XF-73 nasal gel will be applied to each naris twice daily for two days. Each dose will be 0.3mL per naris/0.6mL per dose delivering 0.15mg XF-73 per naris/0.3mg XF-73 per dose. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
Drug: XF-73 nasal gel
Other: Chlorhexidine gluconate 2% topical cloths
Placebo Comparator: Placebo nasal gel
0.3mL nasal gel will be applied to each naris twice daily for two days. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
Drug: Placebo nasal gel
Other: Chlorhexidine gluconate 2% topical cloths



Primary Outcome Measures :
  1. Apparent Eradication of Nasal SA After the Last Dose of XF-73 Based on Semi-quantitative SA Scores From a Broth Enrichment Method. [ Time Frame: The primary endpoint was 48 hours after the last dose (Day 4, 84 hours). ]
    Anti-SA activity was assessed by the quantification of SA colonisation using the broth enriched (semi-quantitative culture) 0-6 point scale. Scores of negative and 0 were interpreted as absence of SA (Responder) and scores of 1 or greater were interpreted as presence of SA (Non-Responder).


Secondary Outcome Measures :
  1. Apparent Eradication of Nasal SA After the Last Dose of XF-73 Based on Semi-quantitative SA Scores From a Broth Enrichment Method. [ Time Frame: Time-points: Day 1(12 hours), Day 2 (24 hours), Day 3 (12 hours after last dose), Day 7 and Day 14. ]
    Anti-SA activity was assessed by the quantification of SA colonisation using the broth enriched (semi-quantitative culture) 0-6 point scale. Scores of negative and 0 were interpreted as absence of SA (Responder) and scores of 1 or greater were interpreted as presence of SA (Non-Responder).

  2. Time-point at Which Clearance Was First Observed From Nasal Swabs Based on Semi-quantitative Score [ Time Frame: Day 1 (12 h), Day 2 (24 h) , Day 3 (12 hours after last dose),Day 4 (48 hours after last dose) ]
    The number of subjects with absence of SA from nasal swabs at the specified time-points..

  3. AUC of the Semi-quantitative SA Scores From Nasal Swabs [ Time Frame: 2 day treatment period; 2 day treatment period up to discharge; 2 day treatment period, discharge and follow-up ]
    Anti-SA activity was assessed by the quantification of SA colonisation using the broth enriched (semi-quantitative culture) 0-6 point scale. Mean changes from baseline (0h) to each timepoint (Day 1,12 h; Day 2, 24 h: Day 3, 48h; Day 4, 84h; Day 7, 144h; Day 14, 312h) were calculated by treatment for the semi-quantitative SA scores. The AUC of the semi-quantitative SA scores were calculated for the two-day treatment period (AUC Day1- Day2); through the two day treatment period and up to discharge (AUC Day 1- Day4); and over the two-day treatment period, discharge and follow-up (AUC Day1- Day14). AUC was calculated by means of a trapezoidal rule using a standard algorithm. A higher AUC is indicative of a higher bacterial growth.

  4. The Number of Participants With Changes in Vital Signs, ECG and Routine Haematology, Clinical Chemistry and Urinalysis Tests. [ Time Frame: Assessed over the two day treatment period and follow-up at 7 and 14 days relative to the first dose. ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Normal, healthy male or female subjects aged between 18 and 75 years.
  2. Subjects confirmed to be persistent nasal SA carriers, defined by 3 separate, SA positive cultures from nasal swabs. Two positive cultures should be obtained at screening visits up to 12 weeks prior to inclusion and at least two weeks apart. The final confirmatory culture should be obtained from a nasal swab on the day of admission to the unit (day -1). Note: Dosing with XF-73 may commence before the result of the day -1 swab is obtained. If the result is negative, the subject should be withdrawn.
  3. Subjects who are able and willing to provide written informed consent to participate in the study
  4. Subjects who have a body mass index (BMI) ≥18.5 kg/m2 and ≤ 32kg/m2.
  5. Subjects who agree not to take part in another clinical trial at any time during the study period.

Exclusion Criteria:

  1. Female subjects who are or may be pregnant or who are lactating.
  2. Subjects who have any acute or chronic illness or infection.
  3. Subjects who have smoked within the 3 months prior to screening.
  4. Subjects who are females of child-bearing potential, defined as being physiologically capable of becoming pregnant, UNLESS using one or more of the following acceptable methods of contraception; established use of oral, injected or implanted hormonal contraception, intrauterine Device (IUD or Coil AND barrier Method (condom or diaphragm or cervical/vault cap) plus spermicidal cream/gel. Contraceptive use should continue throughout the study and for 1 month following completion of the study.
  5. Subjects who are fertile males, defined as all males physiologically capable of conceiving offspring, UNLESS the subject agrees to comply with acceptable contraception e.g. condom plus spermicidal cream/gel. Contraceptive use should continue throughout the study and for 3 months following completion of the study.
  6. Subject with any open wound, lesion, inflammation, erythema or infection affecting the nostrils, nose, upper lip and area of skin close to the nose. This includes herpes simplex lesions and discoid lupus.
  7. Subjects who have a currently symptomatic upper respiratory tract infection, nasopharyngitis, influenza or condition involving increase in nasal secretion such as seasonal or chronic, allergic rhinitis.
  8. Subjects with a history of drug or alcohol abuse in the previous 12 months or who have a positive urine drug test for substances of abuse.
  9. Subjects with a known clinically significant history of atopy or hypersensitivity to any drug or latex.
  10. Subjects with a history of serious illness, cancer or psychiatric condition.
  11. Subjects with known skin photosensitivity.
  12. Subjects with a personal or family history of porphyria.
  13. Subjects who have been treated with or have taken any prescribed or over-the-counter medication within the 14 days prior to admission, with the exception of hormonal contraceptives or hormone replacement therapy.
  14. Subjects who have taken or used topical or systemic antibiotics within the month prior to screening.
  15. Subjects who are known to have serum hepatitis, or who are carriers of the hepatitis B surface antigen (HBsAg) or hepatitis C antibody, or who have a positive result to the test for human immunodeficiency virus (HIV) antibodies
  16. Subjects who have participated in a clinical trial within the last 3 months.
  17. Subjects who have been exposed to XF-73 as part of a previous clinical trial.
  18. Subjects with any clinically significant abnormality in vital signs or laboratory analyses at screening or at baseline, based on the opinion of the investigator.
  19. Subjects with nasal polyps or significant anatomical nasal abnormality.
  20. Subjects with a history of nasal surgery, including cauterization in the last 12 months.
  21. Subjects with a history of multiple episodes [>3] of epistaxis within the last 12 months.
  22. Subjects known to have dermal sensitivity to benzalkonium chloride or other quaternary ammonium disinfectants.
  23. Subjects with in-situ nasal jewellery or open nasal piercings.
  24. Subjects known to have dermal sensitivity to chlorhexidine gluconate (CHG).
  25. Subjects with a history of abnormal bleeding, bruising, frequent nosebleeds or a diagnosis of von Willebrand disease.
  26. Subjects who have or have had an autoimmune disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02282605


Locations
United Kingdom
Quintiles Drug Research Unit
London, United Kingdom, SE11 1YR
Sponsors and Collaborators
Destiny Pharma Plc
Investigators
Study Director: Ian Mr Hayter, BSc Destiny Pharma Plc

Responsible Party: Destiny Pharma Plc
ClinicalTrials.gov Identifier: NCT02282605     History of Changes
Other Study ID Numbers: XF-73B03
First Posted: November 4, 2014    Key Record Dates
Results First Posted: October 7, 2016
Last Update Posted: October 7, 2016
Last Verified: June 2016

Additional relevant MeSH terms:
Staphylococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Chlorhexidine
Chlorhexidine gluconate
Anti-Infective Agents, Local
Anti-Infective Agents
Disinfectants
Dermatologic Agents